Cervical spine chordomas: surgical outcome assessment in a multicenter cohort from the Primary Tumor Research and Outcomes Network
Year: 2026
Type: article
Study design: Observational Study
Abstract: OBJECTIVE: Chordomas are rare, locally aggressive primary neoplasms. Resection with negative margins is the primary recommended therapeutic approach, while adjuvant radiotherapy and chemotherapy can also play a role in their treatment in certain situations, including lesions with positive margins or those that are poorly differentiated or dedifferentiated. Cervical spine chordomas pose significant surgical challenges given their proximity to critical anatomical structures and the mechanical constraints of the cervical spine. In the current case series, authors aimed to explore the clinical and patient-reported outcomes (PROs) of the surgical treatment of cervical chordomas in a large multicenter cohort. METHODS: This multicenter case series analysis utilized data from the prospectively collected Primary Tumor Research and Outcomes Network (PTRON) registry, from its inception (May 16, 2016) to data extraction (February 29, 2024). The study population was restricted to patients with histologically confirmed cervical chordomas involving levels C0-7, who underwent surgical treatment at one of the participating centers, and for whom both the initially planned and postoperatively pathologically confirmed surgical margins were documented. Patient demographics, tumor characteristics, surgical and adjuvant treatments, local recurrence-free survival (LRFS), overall survival (OS), and perioperative adverse events were retrieved. PROs included the Spine Oncology Study Group Outcomes Questionnaire version 2.0 (SOSGOQ2.0), EQ-5D, and SF-36 version 2.0 (SF-36v2). RESULTS: Thirty-eight patients were identified, 12 of whom underwent true en bloc resection (EBR), 18 of whom underwent deliberate intralesional resection, and 8 of whom underwent EBR after intralesional surgery or in whom EBR failed. True EBR led to better LRFS (92% vs 83% vs 63%, respectively) and OS (83% vs 39% vs 50%, respectively). Surgical adverse events within 1 year were more frequent with true EBR (100% vs 39% vs 75%, respectively). EQ-5D, SOSGOQ2.0, and SF-36v2 showed improvement with true EBR, whereas the trends for PROs from the other groups were more variable. CONCLUSIONS: This multicenter case series analysis provides critical insights into the clinical outcomes and PROs in the largest cohort of surgically treated cervical spine chordomas described to date. It underscores the importance and challenges of wide resection for oncological control. It establishes the associated morbidity and provides an overview of PROs following surgery. These findings contribute valuable evidence to inform shared decision-making and optimize patient care.
Source: Journal of Neurosurgery Spine
Authors: Julien F. Zaldivar-Jolissaint, William Chu Kwan, Charles G. Fisher, Laurence D. Rhines, Stefano Boriani, Alessandro Gasbarrini, Alessandro Luzzati, Feng Wei, Ziya L. Gokaslan, Chetan Bettegowda, Daniel M. Sciubba, Aron Lazary, Norio Kawahara, Michelle J. Clarke, Ori Barzilai, Y. Raja Rampersaud, Alexander C. Disch, Dean Chou, John H. Shin, Francis J. Hornicek, Ilya Laufer, Arjun Sahgal, Jorrit-Jan Verlaan, Jeremy Reynolds, Nicolas Dea
Institutions: University of British Columbia, The University of Texas MD Anderson Cancer Center, University of Bologna, Istituto Ortopedico Rizzoli, IRCCS Ospedale Galeazzi - Sant'Ambrogio, Peking University Third Hospital, Brown University, Johns Hopkins University, Johns Hopkins Medicine, Northwell Health, Hofstra University, North Shore University Hospital, Long Island Jewish Medical Center, Buda Health Center, National Center for Spinal Disorders, Kanazawa Medical University, Mayo Clinic, Memorial Sloan Kettering Cancer Center, University of Toronto, Toronto Western Hospital, University Hospital Carl Gustav Carus, Technische Universität Dresden, Columbia University Irving Medical Center, University of Pennsylvania, University of Miami, NYU Langone Health, New York University, Sunnybrook Health Science Centre, Utrecht University, University Medical Center Utrecht, University of Oxford, Oxford University Hospitals NHS Trust
Language: English
Subfield: Rheumatology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Funder: National Cancer Institute
Award: Cancer Center Support Grant
OpenAlex ID: W7126233396
